Purdue University: Eradivir Announces Phase 2 Human Challenge Study of EV25 in Healthy Adults Infected With Influenza
March 08, 2025
March 08, 2025
WEST LAFAYETTE, Indiana, March 8 -- Purdue University issued the following news release:
* * *
Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza
Challenge study follows Phase 1 study that found EV25 is well tolerated in humans
WEST LAFAYETTE, Ind. -- Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therape . . .
* * *
Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza
Challenge study follows Phase 1 study that found EV25 is well tolerated in humans
WEST LAFAYETTE, Ind. -- Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therape . . .